| Name | Title | Contact Details |
|---|
SciTec is a company that provides cutting edge advancements for defense, security, and civil affairs. Their team is committed to delivering advanced sensor systems, data processing algorithms, and testing equipment for defense, national security, and c...
Medica is a non-profit health plan that serves communities in Minnesota, Iowa, Kansas, Missouri, Nebraska, North Dakota, Oklahoma, South Dakota and Wisconsin — the heart of America. As a company, we empower communities by listening to their voices, learning about community needs, and devoting time and resources to help. Medica partners with the communities it serves in many ways, including the Medica Foundation, a nonprofit, charitable grant-making foundation. The Medica Foundation, which provides more than $1 million in grants annually, generally seeks to fund community-based programs and initiatives that can provide sustainable, measurable improvements in the availability, access and quality of health care. To be the trusted health plan of choice for customers, members, partners and our employees. To be trusted in the community for our unwavering commitment to high quality, affordable health care.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Kenzen is pioneering the next generation of personal health monitors and analytics designed to empower its users in the field of health, motion tracking and performance. Utilizing ground-breaking sensor technology initially developed for scientific and aerospace research in Switzerland, Kenzen produces a variety of personal health monitors that wirelessly report data in real time to mobile devices. This data empowers individuals to make critical health decisions when it matters most.
Hyer Medical is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.